Project Name: Pharmacist-led ASCVD and Lipid PC Model of Care with Affinity Care Primary Care Network – Collaborative Working Project

Project Summary: 

The main objective of the Project is to improve the quality of care for patients and support the early identification, review, and medical optimization of patients with Atherosclerotic Cardiovascular Disease (ASCVD) in response to the needs of the PCN.   

The service will be pharmacist led and focus on timely identification of patients with ASCVD including full management reviews and treatment option discussions aiming to achieve:  

1. Identification of sub-optimally treated patients who are not achieving recommended targets for lipid management 

2. Identification of patients who have previously not tolerated or refused alternative lipid modification therapies 

3. Review treatment options in a consultative way with patients 

4. Counsel and optimize patients where appropriate  

Planned Milestones:

  1. Collection of baseline data, in line with the measure of success 

  2. Confirmation of workforce recruitment

  3. Collection of 3 months clinical activity data

  4. Collection of 6 months clinical activity data

  5. Collection of 9 months clinical activity data

  6. Collection of 12 months clinical activity data

  7. Development of business case

  8. Analysis of project data, and submission of Final Project Report

Expected Benefits:

Anticipated benefits for patients:

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.  

  • Enhanced experience and counselling around ASCVD with ongoing management of the condition.  

  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events 

  • Easier access to lipid management care closer to home in the PCN setting 

  • The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, levelling health inequalities within the PCN

Anticipated benefits for partner organisation:

  • Increased proportion of ASCVD patients reviewed by primary care  

  • Increased proportion of ASCVD patients receiving expert and timely review closer to home 

  • Reduction in ASCVD referral rates to secondary care 

  • Increased proportion of patients receiving guideline-directed pharmacotherapy 

  • Insight into benefits of primary care pharmacist led lipid management clinics in primary care and demonstration of benefit via development of business case for substantive funding 

  • Support aligned to NHS Long Term Plan, CDVPREVENT, and Network Contract DES 

Anticipated benefits for Novartis:

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine 

  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life by supporting high quality Collaborative Working with the NHS which addresses the problem of health inequalities 

  • Ethical, professional, and transparent relationship between Novartis and the NHS

Start Date & Duration: July 2022 – 13 months